Philadelphia, U.S. and Oxford, U.K. sites and capabilities spun out of WuXi AppTec
We are excited to share that Altaris completed its acquisition of Advanced Therapies U.S. and OXGENE (together “Advanced Therapies”) on 7 March 2025. Advanced Therapies is now fully owned by Altaris and headquartered in the United States.
Altaris is an investment firm headquartered in New York with an exclusive focus on acquiring and building companies in the healthcare industry. With a 20+ year track record as an owner of healthcare companies, including 11 medical product contract development and manufacturing organizations (CDMOs), Altaris is well-positioned to support Advanced Therapies over its next phase of growth.
This transaction builds on Altaris’ strategic initiative for the cell therapy market, which is focused on delivering life-changing therapies to patients at scale. As part of this strategy, Altaris acquired Minaris Regenerative Medicine (“Minaris”) from Resonac Holdings Corporation in January of this year. Minaris is a cell therapy CDMO with commercially approved manufacturing facilities in the United States, Germany and Japan.
Altaris intends to combine Advanced Therapies and Minaris into a single company, Minaris Advanced Therapies. The combined company’s extensive track record, breadth of capabilities and global manufacturing footprint uniquely position it to deliver accelerated development timelines, reduced manufacturing costs, and greater patient access to life-saving treatments. Altaris expects to complete the operational combination of Minaris and Advanced Therapies in the first half of 2025.
We look forward to introducing the industry to the new Minaris Advanced Therapies which will be a scaled and meaningful contributor to the future of cell therapies. Stay tuned for more updates! Questions? Contact us.